SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 24, 2018
|SECOND SIGHT MEDICAL PRODUCTS, INC.|
|(Exact Name of Registrant as Specified in Its Charter)|
|(State or Other Jurisdiction of Incorporation)|
|(Commission File Number)||(IRS Employer Identification No.)|
12744 San Fernando Road, Suite 400
|(Address of Principal Executive Offices)|
|(Registrant's Telephone Number, Including Area Code)|
|(Former Name or Former Address, if Changed Since Last Report)|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 24, 2018, the Compensation Committee of the Board of Directors of Second Sight Medical Products, Inc. (the “Company”), after reviewing Company’s targeted milestones and performance for the year ended December 31, 2017, approved bonuses for executive and non-executive staff including the following awards to the Company’s executive officers:
|Jonathan Will McGuire||President and CEO||$ 213,070.28|
|Robert J. Greenberg M.D. Ph.D.||Chairman of the Board||$ 147,819.53|
|Thomas B. Miller||Chief Financial Officer||$ 95,301.23|
|Edward Randolph||Vice President, Operations||$ 70,930.80|
|David Jacques||Vice President, R&D||$ 59,732.90|
The awards are based on each of the executives achieving their assigned individual milestones and the Company’s overall performance in 2017.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 30, 2018
SECOND SIGHT MEDICAL PRODUCTS, INC.
/s/ Thomas B. Miller
By: Thomas B. Miller
Chief Financial Officer